Human Rights

Add a title
#F2F2F2
NaN
true
false
Pipe Position
Image
Add a title
#F2F2F2
NaN
false
false
Pipe Position
Image
Add a title
Hex Color
NaN
false
true
left
Image

RGA is committed to respecting human rights by seeking to avoid infringing on the rights of others.

Learn about RGA's Policies

Add a title
#f2f2f2
NaN
false
false
Pipe Position
Image
Add a title
#000000
NaN
false
false
right
Image

Our Commitment


RGA's commitment to human rights is formalized and manifested through our various policies, Code of Conduct, training modules, and ethical business practices. We are committed to working with and encouraging our suppliers, customers, and other business relationships to respect and uphold this commitment.

Our Guiding Principles

Our commitment to human rights is based on the following guiding principles:

Add a title
Hex Color
NaN
false
true
left
Image
  • General Labor Practices: We comply with all applicable labor laws, regulations, and guidelines, including those related to wages, benefits, hiring, promoting, hours worked, and working conditions.
  • Diversity and Inclusion: We value all the individuals in our diverse workforce and recognize the importance of understanding, appreciating, and accepting individual differences.

  • Forced or Compulsory Labor: We do not use or tolerate the use of force, debt-bonded indentured labor, involuntary prison labor, slavery, or any form of human trafficking in our business or supply chain.
  • Workplace Health and Safety: We strive to provide and maintain a healthy and safe working environment that is free from violence, intimidation, or other unsafe or disruptive conditions.

  • Harassment and Non-Discrimination: We believe everyone should be treated with respect and do not tolerate sexual, racial, or other forms of harassment, discrimination, and bullying in the workplace.

  • Privacy: We respect individual privacy expectations and protect the personal information that we collect, use, and disclose in connection with our business.
Add a title
#F2F2F2
NaN
false
false
Pipe Position
Image

Let's Connect

Add a title
#FFFFFF
NaN
false
true
right
Image
required

Add a title
#000000
NaN
false
false
Pipe Position
Image

Our Team is Here
to Help

 

We comply with requirements within the jurisdictions in which we operate, provide appropriate technical and organizational security, and guarantee respect for personal data protection rights around the world. Curious about our policies and governance practices? Contact us. 

 

More Insight from RGA

Cardiovascular Aging: Causes and Intervention
By
  • Hilary Henly
Research and White Papers December 2021

This article is the last in a three-part series, highlighting areas of research funded by the Longer Life Foundation (LLF), a not-for-profit organization that supports the study of scientific and public health factors predicting mortality, morbidity, longevity, ...

Read More
Multi-state Models and their Applications in (Re)insurance
By
  • Kishan Bakrania
  • Chris Falkous
  • Richard Russell
Research and White Papers July 2021

Multi-state models, or MSMs, can help actuaries better characterize individuals as they progress through disease states. RGA's Kishan Bakrania, Chris Falkous, and Richard Russell provide a clear-eyed introduction to this form of modeling and share use cases...

Read More
The Good, the Bad, and the Ugly: Alternative therapies in the prevention and treatment of COVID-19
By
  • Hilary Henly
Research and White Papers February 2021
 Since the start of the pandemic, a number of alternative remedies have emerged that purport to prevent or treat COVID-19, yet have proven to be unsafe or ineffective. Insurers should be aware of serious health complications that can result from many of t...
Read More
COVID-19 Vaccination Scenarios for 2021 and Implications for Life (Re)Insurers: U.S., U.K., and Canada
By
  • Chris Falkous
  • Richard Russell
  • Dr. Daniel D. Zimmerman
Research and White Papers November 2020

Optimism abounds that the first COVID-19 vaccine will soon be approved following interim trial results announced by Pfizer/BioNTech, Moderna, and AstraZeneca/Oxford (for one dosing regimen) showing their vaccines to be at least 90% effective against the disease.

<...
Read More